Safety And Efficacy Of Bosutinib
The objective of this surveillance is to collect information about

1. adverse drug reaction not expected from the LPD (unknown adverse drug reaction)
2. the incidence of adverse drug reactions in this surveillance
3. factors considered to affect the safety and/or efficacy of this drug.
Chronic Myelogenous Leukemia
DRUG: Bosutinib
The incidence of adverse drug reactions, 24 weeks|Cytogenetic response, 24 weeks
The patients should be registered by central registration system.